This Title All WIREs
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 9.182

Nanoparticle‐based applications for cervical cancer treatment in drug delivery, gene editing, and therapeutic cancer vaccines

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract Cervical cancer is a leading cause of gynecological tumor related deaths worldwide. The applications of conventional approaches such as chemoradiotherapy and surgery are restricted due to their side effects and drug resistances. Although immune checkpoint inhibitors (ICIs) have emerged as novel choices, their clinical response rates are rather limited. To date there is a lack of effective treatment regimens for patients with metastatic or recurrent cervical cancer. Recently nanomaterials like liposomes, dendrimers, and polymers are considered as promising delivery carriers with advantages of tumor‐specific administration, reduced toxicity, and improved biocompatibility. Here, we review the applications of nanoparticles in the fields of drug delivery, CRISPR based genome‐editing and therapeutic vaccines in cervical cancer treatment. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Various delivery systems applied in cervical cancer treatment
[ Normal View | Magnified View ]
Overview of experimental pathway for CDDP and miRNA loading. (a) The CDDP was loaded in the liposome shell while miRNA on the surface. (b) Morphology detection of CD/LP‐miCDDP with transmission electron microscopy. (c) Drug release study of CD/LP‐miCDDP in Ph 7.4 and Ph 5.0 conditions. (d) Cellular uptake analysis of CD/LP‐miCDDP and LP‐miCDDP in cervical cancer cells. (e) Plasma concentration–time analysis of CDDP, LP‐miCDDP and CD/LP‐miCDDP. *p <0.05, **p <0.01, ***p <0.0001. Copyright © 2020 SpringerOpen
[ Normal View | Magnified View ]
Systemic administration of lipid‐CRISPR system cleared solid tumors through apoptotic pathway. (a) Binding sites for gRNAs on E6 and E7 genes of HPV. (b) gRNAs (18E7) + Cas9‐lipid effectively eliminated xenografts tumors derived from HeLa cells. (c) The apoptosis ratio was increased in 18E7 group. (d) The lipid‐CRISPR system prolonged mice survival in 18E7 group. Open achieved. Copyright © 2019 Elsevier B.V
[ Normal View | Magnified View ]
Lipid‐mRNA vaccine mediated significantly efficacy in HPV‐positive tumors. E7‐lipid‐mRNA vaccine promoted the infiltration of memory CD8+ T lymphocytes (a), complete remission of HPV16‐positive tumors (b), secretion of proinflammatory factors (c), and inhibition of anti‐PD‐L1 refractory tumors (d). (Reprinted with permission from Grunwitz et al. (2019). Copyright © 2020 Informa UK Limited
[ Normal View | Magnified View ]

Browse by Topic

Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts